The Clinical Trials Core provides integrated management of cancer clinical trials at the Siteman Cancer Center (SCC). The objectives of the Core are to provide an infrastructure and services that: . Support timely completion of investigator-initiated trials by assisting with protocol development, eligibility review, enrollment, clinical monitoring, data management, data analysis and publication. . Maintain quality assurance standards by monitoring accrual and protocol compliance to meet clinical trial objectives. . Support SCC satellites and affiliates with the promotion and management of SCC institutional clinical trials. . Provide comprehensive clinical trial information to all SCC members, especially to multidisciplinary disease focus groups in the Translational and Clinical Research Program and to the multidisciplinary clinic staff who review patients for clinical trials. . Ensure compliance with all institutional, state, and federal regulations in the conduct of SCC institutional clinical trials, including regulatory policies and management of investigational drugs. . Prepare data for NCI, FDA, industry or cancer center quality assurance monitoring and auditing requirements. . Direct continuing education programs for investigators and clinical research staff according to standards of good clinical research practice. . Support SCC investigator participation in cooperative group and industry-initiated studies (on a chargeback basis).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA091842-05
Application #
7117730
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
5
Fiscal Year
2005
Total Cost
$235,510
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Cherian, Mathew A; Olson, Sydney; Sundaramoorthi, Hemalatha et al. (2018) An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem 293:6844-6858
Smith, Lee; Ae Lee, Jung; Mun, Junbae et al. (2018) Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study. Cancer :
Burclaff, Joseph; Mills, Jason C (2018) Plasticity of differentiated cells in wound repair and tumorigenesis, part II: skin and intestine. Dis Model Mech 11:
Ekenga, Christine C; Pérez, Maria; Margenthaler, Julie A et al. (2018) Early-stage breast cancer and employment participation after 2 years of follow-up: A comparison with age-matched controls. Cancer 124:2026-2035
Lin, Huawen; Guo, Suyang; Dutcher, Susan K (2018) RPGRIP1L helps to establish the ciliary gate for entry of proteins. J Cell Sci 131:
Parikh, Rajiv P; Myckatyn, Terence M (2018) Paravertebral blocks and enhanced recovery after surgery protocols in breast reconstructive surgery: patient selection and perspectives. J Pain Res 11:1567-1581
Duan, Chong; Kallehauge, Jesper F; Pérez-Torres, Carlos J et al. (2018) Modeling Dynamic Contrast-Enhanced MRI Data with a Constrained Local AIF. Mol Imaging Biol 20:150-159
Zigler, Rachel E; Madden, Tessa; Ashby, Caitlin et al. (2018) Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users: A Randomized Controlled Trial. Obstet Gynecol 132:888-894
Murali, Bhavna; Ren, Qihao; Luo, Xianmin et al. (2018) Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss. Cancer Res 78:5618-5630
Ahmad, Fahd A; Jeffe, Donna B; Plax, Katie et al. (2018) Characteristics of youth agreeing to electronic sexually transmitted infection risk assessment in the emergency department. Emerg Med J 35:46-51

Showing the most recent 10 out of 1244 publications